Quantifying Serum Derived Differential Expressed and Low Molecular Weight Protein in Breast Cancer Patients

Protein Pept Lett. 2020;27(7):658-673. doi: 10.2174/0929866527666200110155609.

Abstract

Background: Searching the biomarker from complex heterogeneous material for early detection of disease is a challenging task in the field of biomedical sciences.

Objective: The study has been arranged to explore the proteomics serum derived profiling of the differential expressed and low molecular weight protein in breast cancer patient.

Methods: Quantitative proteome was analyzed using the Nano LC/Mass and Bioinformatics tool.

Results: This quantification yields 239 total protein constituting 29% of differentially expressed protein, with 82% downregulated differential protein and 18% up-regulated differential protein. While 12% of total protein were found to be cancer inducing proteins. Gene Ontology (GO) described that the altered proteins with 0-60 kDa mass in nucleus, cytosol, ER, and mitochondria were abundant that chiefly controlled the RNA, DNA, ATP, Ca ion and receptor bindings.

Conclusion: The study demonstrate that the organelle specific, low molecular weighted proteins are significantly important biomarker. That act as strong agents in the prognosis and diagnosis of breast cancer at early stage.

Keywords: Breast cancer; Nano LC/Mass; bioinformatics; gene ontology; low weighted serum protein; proteomics.

MeSH terms

  • Adult
  • Biomarkers, Tumor / blood*
  • Breast Neoplasms / blood*
  • Breast Neoplasms / diagnosis
  • Female
  • Humans
  • Middle Aged
  • Molecular Weight
  • Neoplasm Proteins / blood*
  • Proteomics*

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins